Table 2 Subgroup analysis of the meta-analysis
Outcomes | Subgroup | Number of trials | Effect (95% CI) | Estimate for overall effect | Heterogeneity |
|---|---|---|---|---|---|
Serum PTH concentration | USA | 5 | − 209.57 (− 341.06, − 78.07) | P = 0.002 | I2 = 83.6%, P < 0.001 |
Other country | 3 | −327.13 (− 454.5, − 199.77) | P < 0.001 | I2 = 79.8%, P = 0.007 | |
Patient median age <55 | 5 | − 300.73 (− 417.8, − 183.67) | P < 0.001 | I2 = 67%, P = 0.017 | |
Patient median age ≥55 | 3 | − 211.64 (− 330.57, − 92.72) | P < 0.001 | I2 = 90.6%, P < 0.001 | |
Sample size <200 | 3 | − 235.15 (− 314.24, − 156.05) | P < 0.001 | I2 = 0, P = 0.417 | |
Sample size ≥200 | 5 | − 281.23 (− 385.59, − 176.88) | P < 0.001 | I2 = 87.5%, P < 0.001 | |
Duration of the trial <24 w | 4 | − 289.97 (− 435.79, − 144.15) | P < 0.001 | I2 = 75.5%, P = 0.007 | |
Duration of the trial ≥24 w | 4 | − 235.23 (− 361.52, − 108.95) | P < 0.001 | I2 = 86.4%, P < 0.001 | |
Serum phosphate concentration | USA | 5 | −0.14 (− 0.61, 0.32) | P = 0.544 | I2 = 92.3%, P < 0.001 |
Other country | 4 | −0.51 (− 0.73, − 0.29) | P < 0.001 | I2 = 27.1%, P = 0.249 | |
Patient median age <55 | 4 | −0.41 (− 0.74, − 0.09) | P = 0.013 | I2 = 62.2%, P = 0.047 | |
Patient median age ≥55 | 5 | −0.25 (− 0.71, 0.22) | P = 0.297 | I2 = 92.7%, P < 0.001 | |
Sample size <200 | 3 | − 0.42 (− 0.89, 0.05) | P = 0.081 | I2 = 68.6%, P = 0.042 | |
Sample size ≥200 | 6 | −0.27 (− 0.66, 0.12) | P = 0.175 | I2 = 91.3%, P < 0.001 | |
Duration of the trial <24 w | 4 | − 0.33 (− 0.58, − 0.09) | P = 0.008 | I2 = 24.9%, P = 0.262 | |
Duration of the trial ≥24 w | 5 | −0.30 (− 0.79, 0.19) | P = 0.226 | I2 = 93.8%, P < 0.001 | |
Receiving dialysis | 8 | −0.43 (− 0.58, 0.29) | P < 0.001 | I2 = 32.3%, P = 0.170 | |
Not receiving dialysis | 1 | 0.50 (0.3, 0.7) | P < 0.001 | – | |
Serum calcium phosphorus product | USA | 4 | −4.86 (−10.82, 1.09) | P = 0.109 | I2 = 94.6%, P < 0.001 |
Other country | 4 | −7.15 (−11.88, − 2.41) | P = 0.003 | I2 = 80.5%, P = 0.002 | |
Patient median age <55 | 4 | −5.79 (− 10.91, − 0.66) | P = 0.027 | I2 = 80.4%, P = 0.002 | |
Patient median age ≥55 | 4 | −6.18 (− 11.98, − 0.37) | P = 0.037 | I2 = 95.1%, P < 0.001 | |
Sample size <200 | 3 | - 4.33 (− 10.96, 2.31) | P = 0.201 | I2 = 80.1%, P = 0.007 | |
Sample size ≥200 | 5 | − 6.84 (− 11.77, − 1.91) | P = 0.007 | I2 = 94.2%, P < 0.001 | |
duration of the trial <24 w | 4 | −8.26 (− 11.28, − 5.24) | P < 0.001 | I2 = 48.4%, P = 0.121 | |
duration of the trial ≥24 w | 4 | −3.87 (−9.85, 2.12) | P = 0.206 | I2 = 94.9%, P < 0.001 | |
Receiving dialysis | 7 | −7.29 (−9.77, − 4.81) | P < 0.001 | I2 = 68.6%, P = 0.004 | |
Not receiving dialysis | 1 | 1.20 (− 0.68, 3.08) | P = 0.210 | – |